Lineage Cell Therapeutics, Inc. LCTX
AMEX · United States · Health Technology
$0.9303+0.03 (+2.89%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Rising rates are squeezing indebted businesses. Meet three small cap stocks with strong revenue growth and low debt, plus a screener to find more like them.
CARLSBAD, Calif., September 08, 2026--AlloSCOPE 5D Patent Release
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimiza
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.